Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

624.O2.8 Incorporation of Rituximab into Clinical Management of NHL

Tuesday, December 9, 2008: 7:00 AM-9:00 AM
3007-3009-3011 - West (Moscone Center)
Moderators:
Julie M. Vose, MD and Hervé Tilly, M.D.
7:00 AM
Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom MacroglobulinemiaClinically Relevant Abstract

Irene M. Ghobrial, M.D.1, Jeffrey Matous, MD2*, Swaminathan Padmanabhan, MD3*, Ashraf Badros, MD4*, Robert Schlossman, MD1*, Stacey Chuma, RN1*, Renee Leduc1*, Marybeth Nelson, PA1*, Kelly O'Connor1*, Amy Sam1*, Brianna Harris1*, Jacob Soumerai1*, Diane Warren1*, Ann Birner1*, Nikhil Munshi, MD1*, Steven P. Treon, MD, PhD1*, Kenneth C. Anderson, MD1* and Paul Richardson, MD1*

1Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Rocky Mountain Cancer Center, Denver, CO
3Roswell Park Cancer Center, Buffalo, NY
4University of Maryland, Baltimore, MD

7:15 AM
Rituximab (R) + Hypercvad Alternating with R-Methotrexate/Cytarabine after 9 Years:  Continued High Rate of Failure-Free Survival in Untreated Mantle Cell Lymphoma (MCL)

Jorge Romaguera1, Luis Fayad1*, Alma Rodriguez1*, Fb Hagemeister1*, Barbara Pro1*, Peter McLaughlin1*, Anas Younes1*, Felipe Samaniego1*, Jatin Shah1*, Pamela Weaver1*, Kim Hartig1*, Fernando Cabanillas2*, Larry Kwak1*, Hagop Kantarjian1* and Michael Wang1*

1MD Anderson Cancer Center, Houston, TX
2Cancer Center, San Juan, PR

7:30 AM
Brief Chemoimmunotherapy Rituximab (R)-FND ± R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial

Umberto Vitolo1, Marco Ladetto1, Carola Boccomini1*, Enrica Gamba2*, Isabel Alvarez1*, Luca Baldini1*, Annalisa Chiappella1*, Paolo Corradini1*, Amalia De Renzo1*, Francesco Di Raimondo1*, Andrea Evangelista1*, Andrea Gallamini1*, Attilio Guarini1*, Giuseppe Leone1*, Anna Marina Liberati1*, Barbara Mantoan1*, Maurizio Martelli1*, Lorella Orsucci1*, Guido Parvis1*, Mario Petrini1*, Antonello Pinto1*, Enrico Pogliani1*, Samantha Pozzi1*, Alessandro Pulsoni1*, Luigi Rigacci1*, Corrado Tarella1*, Alessandra Tucci1*, Francesco Zaja1* and Eugenio Gallo1*

1On the behalf of Intergruppo Italiano Linfomi (IIL), Hematology, San Giovanni Battista Hospital and University, Torino, Italy
2Roche-Monza, Italy

7:45 AM
Pentostatin, Cyclophosphamide, and Rituximab (PCR) Achieve High Response Rates in Indolent B-Cell Lyphoma without Prolonged MyelosuppressionClinically Relevant Abstract

Felipe Samaniego, M.D., Michelle Fanale, M.D., Barbara Pro, M.D., F.B. Hagemeister, M.D., Peter McLaughlin, M.D.*, Jorge Romaguera, M.D., Sattva Neelapu, M.D., Maria Alma Rodriguez, M.D., Luis Fayad, M.D., Anas Younes, M.D. and Larry W. Kwak, M.D., Ph.D.

Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX

8:00 AM
Rituximab Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup StudyClinically Relevant Abstract

Marinus H.J. Van Oers, MD, PhD1, Martine Van Glabbeke2*, Liliana Baila, MD2*, Livia Giurgia2*, Richard Klasa3*, Robert E Marcus4*, Max Wolf5, Eva Kimby6* and Anton Hagenbeek1*

1EORTC Lymphoma Group/ HOVON, Amsterdam, Netherlands
2EORTC Data Center, EORTC, Brussels, Belgium
3NCIC CTG Hematology Group, BC, Canada
4BNLI, United Kingdom
5Australasian Leukemia and Lymphoma Group, Australia
6Nordic lymphoma Group, Sweden

8:15 AM
Rituximab Fails to Reduce Histologic Transformation (HT) Rate of Follicular Lymphoma (FL) to Diffuse Large B-Cell Lymphoma (DLBCL)

Ariel E Marciscano1*, Neel Gupta, MD2*, Zhigang Zhang, PhD3*, Julie Teruya-Feldstein, MD4 and Ariela Noy, MD2*

1New York University School of Medicine, New York, NY
2Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
3Memorial Sloan-Kettering Cancer Ctr., Epidemiology-Biostatistics, New York, NY
4Memorial Sloan-Kettering Cancer Center, New York, NY

8:30 AM
Safety, Efficacy and Rituximab Levels Following Chemoimmunotherapy (Rituximab + FAB Chemotherapy) in Children and Adolescents with Mature B-Cell Non-Hodgkin Lymphoma (B-NHL): A Children’s Oncology Group ReportClinically Relevant Abstract

Mitchell S. Cairo, MD1, James Lynch, PhD2*, Lauren Harrison, RN1*, Carmella van de Ven, MS3*, Thomas Gross, MD, PhD4, Bruce Shiramizu, MD5, Warren Sanger, PhD6*, Sherrie L. Perkins, MD, PhD7 and Stanton Goldman, MD8*

1Pediatric Blood and Marrow Transplantation, Columbia University Medical Center, New York, NY
2Univeristy of Nebraska Medical Center, College of Public Health, Children's Oncology Group, Omaha, NE
3Pediatrics, Columbia University Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY
4Nationwide Children's Hospital, The Ohio State University, Columbus, OH
5University of Hawaii, Honolulu, HI
6Department for Human Genetics, University of Nebraska Medical Center, Omaha, NE
7Hematopathology Office, ARUP Laboratories, Salt Lake City, UT
8Medical City Children's, Dallas, TX

8:45 AM
The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study

Marek Trneny, MD, PhD1, Michael Rieger2*, Anders Osterborg, MD, PhD3, Ruth Pettengel4*, Darrell J White, MD5, Devinder Gill, MB, FRCPath, FRACP, FRCPA6, Jan Walewski, MD7*, Evelyn Kuhnt8*, Markus Loeffler, Prof.9*, Michael Pfreundschuh, MD, PhD10 and Anthony D. Ho, M.D., Ph.D.11*

1First Dept. of Medicine, Charles Univ. General Hosp., Prague, Czech Republic
2Departement of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
3Deptartment of Hematology, Karolinska Hospital, Stockholm, Sweden
4Haematology, St Georges Hospital, London
5Dalhousie University, Queen Elizabeth II Health Sciences Ctr., Halifax, NS, Canada
6Dept. of Haematology,Pathology Qld, Princess Alexandra Hospital, Brisbane, Australia
7Central Oncology Institute Nowotworow Ukladu Chlonnego Hospital, Warsaw, Poland
8Coordination Centre for Clinical trials Leipzig, University of Leipzig, Leipzig, Germany
9Institute of Medical Informatics, Statistics and Epidemiology, Leipzig, Germany
10Klinik f. Innere Medizin I, Homburg, Saar, Germany
11Department of Medicine V, University of Heidelberg, Heidelberg, Germany

*signifies non-member of ASH